New drug for relapsed extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new treatment (JK-1201I) against a standard chemotherapy (topotecan) for people with extensive-stage small cell lung cancer that has come back after first-line treatment. The goal is to see if the new treatment works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with small cell lung cancer that has spread (extensive stage).
- You have received exactly one type of chemotherapy that included a platinum drug (like carboplatin or cisplatin), and your cancer got worse within 6 months after that treatment.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself fully or with some help (your daily activity level is good).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new investigational drug (IBB0979) to the standard chemotherapy topotecan helps people with small cell lung cancer whose cancer has come back after earlier treatment. The goal is to see if the combination is more effective than topotecan alone.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
This trial is testing a new combination of two drugs (QLC5508 and QL2107) compared to the standard treatment (tislelizumab plus chemotherapy) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the new combination works better at controlling the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.